AKT1 and neoplasm: Detection of at least one PI3K/AKT/PTEN pathway alteration in baseline plasma sample was not correlated with response to treatment when assessed alone (P = 0.70) or in combination with tumor status (PIK3CA or AKT1 mutations or PTEN deletion, P = 1).